NASDAQ:APVO Aptevo Therapeutics Q3 2025 Earnings Results & Report $1.79 -0.01 (-0.56%) Closing price 03:55 PM EasternExtended Trading$1.81 +0.02 (+1.12%) As of 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Aptevo Therapeutics missed analyst earnings expectations in its Q3 2025 results, released November 6, 2025. The company reported EPS of -$40.14 versus the -$37.62 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2025Report DateNovember 6, 2025TimeBefore Market Opens Aptevo Therapeutics EPS ResultsActual EPS-$40.14Consensus EPS -$37.62Beat/MissMissed by -$2.52One Year Ago EPSN/AAptevo Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsAptevo Therapeutics' next earnings date is estimated for Thursday, November 5, 2026, based on past reporting schedules. Conference Call ResourcesEarnings HistoryCompany Profile Aptevo Therapeutics Q3 2025 Earnings FAQ Did Aptevo Therapeutics beat earnings estimates for Q3 2025? Aptevo Therapeutics (NASDAQ:APVO) reported earnings of -$40.14 per share for Q3 2025, missing the consensus estimate of -$37.62. The report was announced on Thursday, November 6, 2025. When is Aptevo Therapeutics' next earnings date? Aptevo Therapeutics' next earnings date is estimated for Thursday, November 5, 2026. MarketBeat tracks confirmed and estimated earnings dates for Aptevo Therapeutics on the company's earnings history page. Aptevo Therapeutics Earnings HeadlinesAptevo Reports 93% Clinical Benefit With Mipletamig Triplet In TP53-Mutated AML; Stock Down 17%September 3, 2026 | rttnews.comAptevo reports 93% clinical benefit rate for Mipletamig triplet in TP53-mutated AMLSeptember 3, 2026 | msn.comDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in could be a costly mistake. He calls it among the most overhyped, overvalued large-cap offerings ever pushed onto everyday investors. Tilson believes a rare economic event is approaching - one with serious consequences for your portfolio this summer. He has prepared a free analysis outlining what he sees and the specific steps he recommends taking now.October 9 at 1:00 AM | Stansberry Research (Ad)APVO: Focusing on Three Key Areas of DevelopmentAugust 24, 2026 | finance.yahoo.comAptevo Shareholders Back Board, Auditor and Incentive PlanAugust 21, 2026 | tipranks.comAptevo APVO Reports Q2 2026 Update With $9.8 Million CashAugust 14, 2026 | quiverquant.comQSee More Aptevo Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Aptevo Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Aptevo Therapeutics and other key companies, straight to your email. Email Address About Aptevo TherapeuticsAptevo Therapeutics (NASDAQ:APVO) is a clinical-stage biotechnology company focused on developing targeted immunotherapies for cancer and other serious diseases. The company’s research programs are designed to harness the immune system by directing immune cells toward specific disease-associated targets. Aptevo’s pipeline is built primarily around its proprietary ADAPTIR bispecific antibody technology, which is intended to create therapeutic antibodies capable of binding to two different targets. Its investigational programs have included APVO436, an immune-cell engager targeting CD123 and CD3 for potential treatment of hematologic malignancies such as acute myeloid leukemia and myelodysplastic syndromes, as well as other preclinical and clinical immuno-oncology candidates. The company was established as an independent business in 2016 through a separation from Emergent BioSolutions. Aptevo initially marketed IXINITY, a recombinant factor IX therapy for hemophilia B, before transitioning its strategic focus toward oncology and other targeted immunotherapies. Aptevo is headquartered in Seattle, Washington, and conducts its research and development activities through collaborations and clinical programs intended for patients in the United States and other international markets.View Aptevo Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Palantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November EarningsApplied Digital’s Hidden Moat Could Unlock Massive UpsideLevi's Stock Dip Reveals Value Opportunity Despite Q3 HeadwindsTilray Finds a Path to Growth Without Waiting on U.S. Cannabis ReformPepsiCo Stock Looks Poised to Bottom With High Yield, Deep ValueMicrosoft Is Almost Back to $555—Now the Hard Part BeginsSkydance Just Became a Media Giant—With an $80 Billion Debt Load Upcoming Earnings Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
